Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;7(8):836-843.
doi: 10.1001/jamacardio.2022.1876.

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Martin Bødtker Mortensen  1   2   3   4 , Anne Tybjærg-Hansen  3   4   5 , Børge G Nordestgaard  2   3   4
Affiliations

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Martin Bødtker Mortensen et al. JAMA Cardiol. .

Abstract

Importance: For primary prevention of atherosclerotic cardiovascular disease (ASCVD), the 2021 European Society of Cardiology (ESC) guidelines on statin use (hereafter European-ESC) recommend a new risk model (Systematic Coronary Risk Evaluation 2 [European-SCORE2]) as well as new age-specific treatment thresholds (≥7.5% 10-year ASCVD risk if aged 40-49 years and ≥10% if aged 50-69 years).

Objective: To compare the clinical performance of the 2021 European-ESC, American College of Cardiology/American Heart Association (hereafter US-ACC/AHA), UK National Institute for Health and Care Excellence (UK-NICE), and 2019 ESC/European Atherosclerosis Society (EAS) guidelines in apparently healthy individuals.

Design, setting, and participants: This population-based contemporary cohort study included 66 909 individuals from the Copenhagen General Population Study. Participants were aged 40 to 69 years and were free of ASCVD, diabetes, chronic kidney disease, and statin use at baseline in 2003 to 2015. Mean follow-up time was 9.2 years. Data were analyzed from November 2021 to April 2022.

Exposures: Statin treatment according to guideline criteria.

Main outcomes and measures: Calibration of risk calculators, statin eligibility, sensitivity, and specificity for ASCVD events according to guideline criteria.

Results: During follow-up, a range of 2962 to 4277 nonfatal and fatal ASCVD events was observed, as defined by the 2021 European-SCORE2, US pooled cohort equations (PCE), and UK-QRISK3 models, and 180 fatal ASCVD events were noted as defined by the 2019 European-SCORE1 model. European-SCORE2 was slightly better calibrated with a predicted/observed ASCVD event ratio of 0.8 vs 1.3 for US-PCE, 1.3 for UK-QRISK3, and 5.8 for European-SCORE1. For primary prevention class I recommendations in individuals aged 40 to 69 years, 2862 of 66 909 (4%) qualified for statins according to the 2021 European-ESC guidelines compared with 23 029 (34%) with US-ACC/AHA, 17 659 (26%) with UK-NICE, and 13 496 (20%) with 2019 European-ESC/EAS guidelines, with associated sensitivities for detecting future European-SCORE2-defined ASCVD events of 12%, 60%, 51%, and 36%, respectively. The sensitivity of the European-ESC guidelines was improved considerably by lowering the treatment thresholds, resulting in smaller losses in specificity. To obtain similar clinical performance with the 2021 European-ESC guidelines as in the other guidelines, the threshold with European-SCORE2 should be reduced to 5% overall to match US-ACC/AHA, to 6% to match UK-NICE, and to 7% to match 2019 European-ESC/EAS guidelines.

Conclusions and relevance: Despite an improved European-SCORE2 prediction model, the new treatment thresholds in the 2021 European-ESC guidelines dramatically reduce eligibility for primary prevention with statins in low-risk European countries. Using lower treatment thresholds can improve overall guideline performance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tybjærg-Hansen reported consultant or speaking fees from Akcea, Amgen, AstraZeneca, Draupnir Bio, Novartis, Regeneron, Sanofi, and Silence Therapeutics outside the submitted work. Dr Nordestgaard reported consultant or speaking fees from Akcea, Amgen, Amarin, AstraZeneca, Denka, Esperion, Kowa, Novartis, Novo Nordisk, Regeneron, Sanofi, and Silence Therapeutics outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Statin Eligibility for Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) and Sensitivity and Specificity for Detecting ASCVD Events According to Guideline-Defined Class I/Strong Recommendations in Individuals Aged 40 to 69 Years
Based on 66 909 individuals from the Copenhagen General Population Study who were free of ASCVD, diabetes, chronic kidney disease, and statin use at baseline. ACC/AHA indicates American College of Cardiology and American Heart Association; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence.
Figure 2.
Figure 2.. Statin Eligibility for Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) Stratified by Sex and 5-Year Age Groups According to Guideline-Defined Class I/Strong Recommendations in Individuals Aged 40 to 69 Years
Based on 66 909 individuals from the Copenhagen General Population Study who were free of ASCVD, diabetes, chronic kidney disease, and statin use at baseline. ACC/AHA indicates American College of Cardiology and American Heart Association; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence.
See this image and copyright information in PMC

Comment in

  • doi: 10.1001/jamacardio.2022.1883

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mortensen MB, Nordestgaard BG. Comparison of five major guidelines for statin use in primary prevention in a contemporary general population. Ann Intern Med. 2018;168(2):85-92. doi:10.7326/M17-0681 - DOI - PubMed
    1. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121(15):1768-1777. doi:10.1161/circulationaha.109.849166 - DOI - PubMed
    1. Conroy RM, Pyörälä K, Fitzgerald AP, et al. ; SCORE project group . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. doi:10.1016/S0195-668X(03)00114-3 - DOI - PubMed
    1. Mortensen MB, Falk E. Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention. Eur Heart J. 2017;38(29):2259-2263. - PMC - PubMed
    1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2935-2959. doi:10.1016/j.jacc.2013.11.005 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances